Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 6/20 | 0.47 |
| ▸ | GPR132 | Q9UNW8 | 6/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.42 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616100 | 0.90 | TAS1R3 (0.48) | FFAR1FFAR4PPARDGPR132PPARG | |
| SCHEMBL4616574 | 0.84 | PPARG (0.61) | PPARDGPR132PPARGPPARAALDH1A1 | |
| SCHEMBL4617143 | 0.83 | PPARG (0.53) | FFAR1FFAR4PPARDGPR132PPARG | |
| SCHEMBL5429402 | 0.78 | MMP13 (0.53) | PPARDPPARGPPARAALDH1A1SMN1; SMN2 | |
| SCHEMBL4616750 | 0.77 | PPARD (0.51) | FFAR1FFAR4PPARDPPARGPPARA | |
| SCHEMBL4616034 | 0.76 | PPARG (0.53) | PPARDPPARGPPARALMNASMN1; SMN2 | |
| SCHEMBL4635056 | 0.75 | PPARG (0.55) | PPARDPPARGPPARAALDH1A1LMNA | |
| SCHEMBL4616353 | 0.75 | PPARD (0.64) | PPARDPPARGPPARA | |
| SCHEMBL5422967 | 0.74 | LPAR1 (0.57) | FFAR1FFAR4PPARDPPARGPPARA | |
| SCHEMBL4613874 | 0.74 | MRGPRX4 (0.65) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| EP-1697304-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | FFAR1 11/4885FFAR4 23/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.